Rhythm Pharmaceuticals, Inc. RYTM

US Biotechnology

$114.17 ▲ +0.20% (+$0.23)

🎢 High Beta

Open $113.91

Prev Close $113.94

Day Range $112.50 – $114.50

52W Range $74.50 – $122.20

Market Cap $7.90B

Beta 2.09

EPS (TTM) $-2.85

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2017-10-05
Shares Out.	68,850,000
Website	rhythmtx.com ↗
Phone	18572644280
Employees	414
Revenue	$92.1M
Gross Profit	$80.0M
Net Income	-$41.4M
Free Cash Flow	-$83.2M
Total Assets	$443.1M
Total Liabilities	$241.6M
Equity	$201.5M

About Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Rhythm Pharmaceuticals, Inc. is a publicly traded company under the ticker symbol RYTM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.